Transcatheter aortic valve replacement: a palliative approach to infective endocarditis.
Christine P ShenMarissa A MunsayacAustin A RobinsonCurtiss T StinisPublished in: BMJ case reports (2022)
An 88-year-old man with small lymphocytic lymphoma presented to the hospital with shortness of breath and was diagnosed with heart failure. Serial blood cultures and echocardiography revealed Staphylococcus epidermidis endocarditis, complicated by severe aortic regurgitation. Despite intravenous antibiotic therapy and aggressive intravenous diuresis therapy in the hospital, he decompensated into cardiogenic shock, requiring invasive haemodynamic monitoring and inotrope therapy. With multidisciplinary discussion involving the patient and his children, there was a joint decision that at his advanced age, he would not pursue surgical aortic valve replacement and instead proceed with a transcatheter aortic valve replacement (TAVR) with palliative intent. He underwent TAVR with subsequent symptomatic and functional improvement as well as resolution of cardiogenic shock.
Keyphrases
- transcatheter aortic valve replacement
- aortic valve
- aortic stenosis
- aortic valve replacement
- transcatheter aortic valve implantation
- heart failure
- left ventricular
- ejection fraction
- healthcare
- staphylococcus aureus
- young adults
- biofilm formation
- computed tomography
- stem cells
- coronary artery disease
- high dose
- escherichia coli
- emergency department
- low dose
- case report
- single cell
- cardiac resynchronization therapy
- decision making
- pseudomonas aeruginosa
- atrial fibrillation
- mesenchymal stem cells
- drug induced
- acute heart failure